BACKGROUND: Few studies have described improvement in health-related quality of life (HRQOL) associated with opioid dependence treatment with buprenorphine (ODT-B). OBJECTIVE: To evaluate HRQOL changes in domain scores, physical and mental component summaries, and health utilities (HUs) associated with ODT-B using the Short Form 36 (SF-36). METHODS: We assessed HRQOL changes in a substudy of a pharmacokinetic study that compared buprenorphine oral tablet and liquid dosage formulations over 16 weeks. Individuals, aged 18-65 years, were screened for opioid dependence. They were excluded if they would not agree to birth control or had a serious medical condition. Subjects received psychosocial counseling and weekly group therapy. The SF-36 was administered upon enrollment and at 4-week intervals. We used the SF-6D to estimate HUs. We performed intention to treat (ITT) analyses based on the last observation available for each subject. Paired t tests of each domain and HU, limited to remaining patients at each 4-week interval, were also conducted. RESULTS: Of 96 subjects enrolled, cumulative dropouts over time resulted in 80, 69, 59, and 44 subjects remaining at 4, 8, 12, and 16 weeks. There were no significant differences in opioid-positive urines, dropout rates, or dosage changes between formulations. In the ITT analyses, HRQOL improvements over time were bodily pain (62.1 vs. 69.1, P = 0.017), vitality (49.8 vs. 56.5, P = 0.001), mental health (59.9 vs. 66.0, P = 0.001), social function (66.4 vs. 74.7, P = 0.001), role emotional (59.4 vs. 71.9, P = 0.003), role physical (60.9 vs. 70.6, P = 0.005), and mental component summary (41.9 vs. 45.4, P<0.001). HU scores also improved (0.674 vs. 0.715, P = 0.001). Results from paired t tests, with only concurrently enrolled patients, showed similar improvements from baseline to 4, 8, 12, or 16 weeks. CONCLUSION: Buprenorphine, accompanied with psychosocial counseling, was associated with improved HRQOL and HUs.
BACKGROUND: Few studies have described improvement in health-related quality of life (HRQOL) associated with opioid dependence treatment with buprenorphine (ODT-B). OBJECTIVE: To evaluate HRQOL changes in domain scores, physical and mental component summaries, and health utilities (HUs) associated with ODT-B using the Short Form 36 (SF-36). METHODS: We assessed HRQOL changes in a substudy of a pharmacokinetic study that compared buprenorphine oral tablet and liquid dosage formulations over 16 weeks. Individuals, aged 18-65 years, were screened for opioid dependence. They were excluded if they would not agree to birth control or had a serious medical condition. Subjects received psychosocial counseling and weekly group therapy. The SF-36 was administered upon enrollment and at 4-week intervals. We used the SF-6D to estimate HUs. We performed intention to treat (ITT) analyses based on the last observation available for each subject. Paired t tests of each domain and HU, limited to remaining patients at each 4-week interval, were also conducted. RESULTS: Of 96 subjects enrolled, cumulative dropouts over time resulted in 80, 69, 59, and 44 subjects remaining at 4, 8, 12, and 16 weeks. There were no significant differences in opioid-positive urines, dropout rates, or dosage changes between formulations. In the ITT analyses, HRQOL improvements over time were bodily pain (62.1 vs. 69.1, P = 0.017), vitality (49.8 vs. 56.5, P = 0.001), mental health (59.9 vs. 66.0, P = 0.001), social function (66.4 vs. 74.7, P = 0.001), role emotional (59.4 vs. 71.9, P = 0.003), role physical (60.9 vs. 70.6, P = 0.005), and mental component summary (41.9 vs. 45.4, P<0.001). HU scores also improved (0.674 vs. 0.715, P = 0.001). Results from paired t tests, with only concurrently enrolled patients, showed similar improvements from baseline to 4, 8, 12, or 16 weeks. CONCLUSION:Buprenorphine, accompanied with psychosocial counseling, was associated with improved HRQOL and HUs.
Authors: Dinesh Khanna; Daniel E Furst; Weng Kee Wong; Joel Tsevat; Philip J Clements; Grace S Park; Arnold E Postlethwaite; Mansoor Ahmed; Shaari Ginsburg; Ron D Hays Journal: Qual Life Res Date: 2007-04-03 Impact factor: 4.147
Authors: I-Chan Huang; Richard J Willke; Mark J Atkinson; William R Lenderking; Constantine Frangakis; Albert W Wu Journal: Qual Life Res Date: 2007-04-06 Impact factor: 4.147
Authors: M J Harrison; L M Davies; N J Bansback; M J McCoy; S M M Verstappen; K Watson; D P M Symmons Journal: Qual Life Res Date: 2009-09-24 Impact factor: 4.147
Authors: James Bell; Marian Shanahan; Carolyn Mutch; Felicity Rea; Anni Ryan; Robert Batey; Adrian Dunlop; Adam Winstock Journal: Addiction Date: 2007-09-03 Impact factor: 6.526
Authors: Bonsan Bonne Lee; Madeleine T King; Judy M Simpson; Mark J Haran; Martin R Stockler; Obaydullah Marial; Glenn Salkeld Journal: Value Health Date: 2008-01-11 Impact factor: 5.725
Authors: Shannon Gwin Mitchell; Jan Gryczynski; Robert P Schwartz; C Patrick Myers; Kevin E O'Grady; Yngvild K Olsen; Jerome H Jaffe Journal: J Psychoactive Drugs Date: 2015 Apr-Jun
Authors: Jose Martinez-Raga; Francisco Gonzalez-Saiz; Julian Oñate; Itziar Oyagüez; Eliazar Sabater; Miguel A Casado Journal: Health Econ Rev Date: 2012-03-29
Authors: Adrian R Pasareanu; Anne Opsal; John-Kåre Vederhus; Øistein Kristensen; Thomas Clausen Journal: Health Qual Life Outcomes Date: 2015-03-14 Impact factor: 3.186
Authors: Antonio J Rojas; Oscar Lozano; Katia Foresti; Elham Zolfaghari; Carlos Zubaran Journal: Health Qual Life Outcomes Date: 2015-11-19 Impact factor: 3.186